HAVN Life Sciences Inc
HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psil… Read more
HAVN Life Sciences Inc (HAVLF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of January 2023: 0.345x
Based on the latest financial reports, HAVN Life Sciences Inc (HAVLF) has a cash flow conversion efficiency ratio of 0.345x as of January 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($289.12K) by net assets ($837.82K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
HAVN Life Sciences Inc - Cash Flow Conversion Efficiency Trend (2020–2022)
This chart illustrates how HAVN Life Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
HAVN Life Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HAVN Life Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SysGroup PLC
LSE:SYS
|
-0.014x |
|
CARAVEL MIN
BE:STC
|
N/A |
|
HAPPY WORLD PROPERTY LTD
SEM:HWP
|
N/A |
|
TULLOW OIL (TQW.SG)
STU:TQW
|
-1.003x |
|
AFRICAN DOMESTIC BOND FUND ETF - (USD)
SEM:ADBF
|
N/A |
|
LAPTRUST IMARA I-REIT
XNAI:LAPTRUST
|
N/A |
|
Namliong SkyCosmos Inc
PINK:NLSC
|
0.001x |
|
Egypt for Poultry
EGX:EPCO
|
N/A |
Annual Cash Flow Conversion Efficiency for HAVN Life Sciences Inc (2020–2022)
The table below shows the annual cash flow conversion efficiency of HAVN Life Sciences Inc from 2020 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-04-30 | $3.14 Million | $-7.88 Million | -2.507x | -217.55% |
| 2021-04-30 | $13.20 Million | $-10.42 Million | -0.790x | -1901.29% |
| 2020-04-30 | $1.90 Million | $-75.02K | -0.039x | -- |